Effect of shRNA mediated Smad4 gene silencing on the fibrosis of C2C12 myoblasts
Effect of shRNA mediated Smad4 gene silencing on the fibrosis of C2C12 myoblasts
复制标题
shRNA介导的Smad4基因沉默对C2C12成肌细胞纤维化的影响
DOI:
10.2478/v10136-011-0023-2
复制
发表时间:
2012-01-01
期刊:
影响因子:
--
通讯作者:
Jiang, Jia
中科院分区:
文献类型:
--
作者:
Chen, Shiqiu;Chen, Jiwu;Jiang, Jia
Our present study aimed to investigate the effect of lentiviral-mediated RNAi using shRNA targeting Smad4 on TGF-beta 1 induced fibrosis. shRNAs targeting Smad4 were designed and the most efficient shRNA was screened. This shRNA was introduced into a lentiviral vector which was used to infect C2C12 myoblasts, and then the Smad4 expression was detected. Cells were divided into: C2C12 cells group, TGF-beta 1 induction group, transfection group, and transfection after TGF-beta 1 induction group. C2C12 myoblasts were transfected with lentivirus carrying Smad4-shRNA and treated with TGF-beta 1 to induce the differentiation into myofibroblasts. Fluorescence real-time-PCR and the western blot assay were employed to detect the expressions of collagen I and alpha-SMA. The results showed that the protein and mRNA expression of Smad4 in the C2C12 cells transfected with Smad4-shRNA1 was significantly reduced when compared with C2C12 before transfection. In the TGF-beta 1 induction group, the mRNA expressions of alpha-SMA and collagen I were significantly increased as compared to the C2C12 cells group. In the transfection after TGF-beta 1 induction group, the mRNA expressions of alpha-SMA and collagen I were significantly increased compared to the transfection group, and the protein expressions significantly increased, respectively. In the transfection after TGF-beta 1 induction group, the mRNA expressions of alpha-SMA and collagen I were significantly decreased compared to the TGF-beta 1 induction group, and the protein expressions significantly reduced, respectively. The results indicate that suppression of Smad4 expression can efficiently inhibit the TGF-beta 1 induced fibrosis in myoblasts. The findings suggest Smad4 may become a novel target for the treatment of skeletal muscle fibrosis.